Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Revealed: women GPs shut out from corridors of power

GPs can use strontium ranelate for primary and secondary prevention of osteoporosis, but

only as a second-line treatment, NICE has provisionally ruled.

Women with appropriate risk factors and T-scores can receive the drug if bisphosphonates are contraindicated or patients have not responded to them, the institute's draft update on secondary prevention recommends.

New draft guidance on primary prevention also suggests second-line use in the relevant age groups, according to T-score and risk factors.

But Dr Pam Brown, vice-chair of the primary care forum of the National Osteoporosis Society and a GP in Swansea, said: ‘It is not clear why strontium ranelate has been relegated to use only as an alternative to bisphosphonates.'

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say